2025-522097-36-00招募中1 期
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, MULTIPLE RISING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF DEURUXOLITINIB IN HEALTHY ADULTS
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 30
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Vera Cigler
Scientific
Sun Pharmaceutical Industries Inc.
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
不适用
STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF 04236921 IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)EUCTR2011-000420-15-HUPfizer Inc.235 East 42nd Street, New York, NY 10017180
已完成
不适用
A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTRIC STUDY TO EVALUATE THE EFFECTS OF ROFECOXIB IN REDUCING THE RISK OF PROSTATE CANCER (VIP STUDY).PER-047-03ELI LILLY INTERAMERICA INC.,
进行中（未招募）
1 期
A STUDY OF CO-ADMINISTRATION OF TESOFENSINE/ METOPROLOL TREATMENT IN SUBJECTS WITH TYPE 2 DIABETES MELLITUSDiabetes mellitus type 2MedDRA version: 18.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861EUCTR2015-005522-19-DESaniona, A/S60
未知
不适用
A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, CROSSOVER STUDY OF MK-1029 IN ADLTS SUBJECTS WITH PERSISTENT ASTHMA WHO REMAIN UNCONTROLLED WHILE BEING MAINTAINED ON MONTELUKAST.PER-098-12MERCK SHARP & DOHME PERU S.R.L.,33
进行中（未招募）
不适用
A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF 04236921 IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)Symptoms, signs and abnormal clinical and laboratory findings, NECKCT0000909Pfizer Korea180